LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
=== Explosives === Guncotton CE/TNT Nobel 808 plastic explosive Nobel 851 plastic explosive Nobel 852 plastic explosive PE2 plastic explosive SX2 sheet explosive PE3 plastic explosive PE3A plastic explosive PE4 plastic explosive - Both as individual sticks and as a slab charge (L3A1) No. 1 Mk 3-6 6 Inch Beehive Demolition Charge No. 2 Mk 1 General Wade Arched Demolition Charge No. 3 Mk 1 Hayrick Demolition Charge No. 11 Mk 1 Beehive Demolition Charge No. 14 Mk 1 Hayrick Demolition Charge - Both as individual charges and as part of the L1A1 Necklace Charge kit Bangalore torpedo No. 1 Baby Viper Mine Clearing Line Charge
==== Commander of the Order of the British Empire (CBE) ==== Military Division Royal Navy Captain Paul Branscombe, . Captain William Keith Hutchison. Captain Keith Frank Read. Army Major General Cedric Norman George Delves, , (485712), late The Devonshire and Dorset Regiment. Brigadier Kevin John Watson Goad, , (472543), late Royal Army Ordnance Corps. Colonel (Acting Brigadier) Keith Skempton (487055), late The Cheshire Regiment. Colonel (Acting Brigadier) Albert Edward Whitley, , (495259), late Corps of Royal Engineers. Royal Air Force Group Captain Roger Hubert Beazley, , (Retired). Group Captain George William Gibson, (Retired). Air Commodore Ernest William Tyack. Civil Division John Edwin Adshead. For services to the National Training Awards and to Vocational Training. Nicholas Kenneth Alston, Assistant Secretary, Ministry of Defence. Michael Day Beaumont, . For political and public service. Arthur John Armstrong Bell. For political and public service. Alastair John Bellingham, Professor of Haematology, King's College Hospital School of Medicine and Dentistry. For services to Medicine and to the Royal College of Pathologists. Professor Sushantha Kumar Bhattacharyya, Professor of Manufacturing Systems Engineering, University of Warwick. For services to Industry and to Technology. John David Stuart Brown, . For political and public service. Christopher John Skidmore Burd. For services to the Forestry Industry. David Thomas Burke, Expert Special Adviser on the Environment, Department of the Environment. David Adam Cairns, Music Critic, The Sunday Times.
==== 2026 Iran war ==== Kiggans has strongly supported the Trump administration in the 2026 Iran war, also known as Operation Epic Fury. Kiggans stated in March 2026 that the goals of the war include "destroying Iran's ballistic missile capability, destroying their navy, and destroying their ability to have nuclear weapons." In June 2026, Kiggans voted against a war powers resolution that would have limited the president's ability to wage war in Iran without congressional consent.
=== Pervasive expression === With the development of technologies such as RNA-seq and Ribo-seq, eukaryotic genomes are now known to be pervasively transcribed and translated. Many ORFs that are either unannotated, or annotated as long non-coding RNAs (lncRNAs), are translated at some level, either in a condition or tissue-specific manner. Though infrequent, these translation events expose non-genic sequence to selection. This pervasive expression forms the basis for several models describing de novo gene birth. It has been speculated that the epigenetic landscape of de novo genes in the early stages of formation may be particularly variable between and among populations, resulting in variable gene expression thereby allowing young genes to explore the "expression landscape." The QQS gene in A. thaliana is one example of this phenomenon; its expression is negatively regulated by DNA methylation that, while heritable for several generations, varies widely in its levels both among natural accessions and within wild populations. Epigenetics are also largely responsible for the permissive transcriptional environment in the testes, particularly through the incorporation into nucleosomes of non-canonical histone variants that are replaced by histone-like protamines during spermatogenesis.
Incidences of partial recoil occurred at 1-week post-procedure, with no further, significant, breast volume decrease afterwards, nor at the follow-up treatment at 30-weeks post-procedure. The stable, long-term increase in breast size was 55 percent (range 15–115%). The MRI visualizations of the breasts showed no edema, and confirmed the proportionate enlargement of the adipose and glandular components of the breast-tissue matrices. Furthermore, a statistically significant decrease in body weight occurred during the study, and self-esteem questionnaire scores improved from the initial-measure scores. Because external vacuum expansion of the recipient-site tissues permits injecting large-volume fat grafts (+300 cc) to correct defects and enhance the bust, the histologic viability of the breast filler (adipocyte fat) and its volume must be monitored and maintained. The long-term, volume maintenance data reported in Breast Augmentation using Pre-expansion and Autologous Fat Transplantation: a Clinical Radiological Study (2010) indicate the technical effectiveness of external tissue expansion of the recipient site for a 25-patient study group, who had 46 breasts augmented with fat grafts. The indications included micromastia (underdevelopment), explantation deformity (empty implant pocket), and congenital defects (tuberous breast deformity, Poland's syndrome).
Sources: en.wikipedia.org
=== Cachexia and malnutrition === Cachexia and malnutrition are related but not the same. Malnutrition happens when the body doesn't get enough nutrients, leading to changes in body weight, physical strength, and mental function. Malnutrition includes both disease-related malnutrition as well as malnutrition without disease such as seen in starvation or aging. Cachexia should be viewed as a type of malnutrition in which inflammation from a long-term illness causes unwanted muscle loss.
== External links == Jewish State.com Zionism, News, Links Israeli Jewish scene from ynetnews Israel as a Jewish state from the Jerusalem Center for Public Affairs 'Israel a Jewish state first', says former High Court Justice Dalia Dorner
== Medical uses == Fosfomycin is used to treat bladder infections as well as urinary tract infections (UTIs), where it is usually given as a single dose by mouth. Oral fosfomycin is not recommended for children under 12 years old. Additional uses have been proposed. The global problem of advancing antimicrobial resistance has led to a renewed interest in its use more recently. Fosfomycin can be used as an efficacious treatment for both UTIs and complicated UTIs including acute pyelonephritis. The standard regimen for complicated UTIs is an oral 3 g dose administered once every 48 or 72 hours for a total of 3 doses or a 6 g dose every 8 hours for 7–14 days when fosfomycin is given in IV form. Intravenous fosfomycin is being increasingly used for treating infections caused by multidrug-resistant bacteria, mostly as a partner drug in order to avoid the occurrence of resistances and to take advantage of its synergistic activity with several other antimicrobials. In real-life settings, intravenous fosfomycin is most commonly used to treat pneumonia (34%), bloodstream infections (22%), and urinary tract infections (21%). In the majority of cases, it is administered in combination with a beta-lactam antibiotic, and in approximately half of the cases, it is employed as empirical therapy. Daily adult dose usually ranges from 12 to 24 grams. When administered in continuous infusion, a loading dose of fosfomycin 8 g followed by a daily dose of 16 g or 24 g. Continuous infusion is suggested in patients with normal renal function.
=== Phosphatase recruitment === Phosphorylated amino acids are crucial for the modulation of the binding of transcription factors and other gene regulatory proteins. Pin1's effect on isomerization of proline residues leads to an increase or decrease in recruitment of phosphatases, namely Scp1 and Ssu72 and their recruitment to the RNAP II CTD. The cis-Pro formation is associated with an increase in Ssu72. Scp1 on recognizes trans-Pro formations, and is not affected by such isomerization. Pin1 also triggers the activation of the DSIF complex and NELF, which are responsible for pausing RNAP II in mammalian cells, and their conversion into positive elongation factors, facilitating elongation. This potentially could be an isomerization dependent process.
Sources: en.wikipedia.org
== Buffers == Buffers in gel electrophoresis are used to provide ions that carry a current and to maintain the pH at a relatively constant value. These buffers have plenty of ions in them, which is necessary for the passage of electricity through them. Something like distilled water or benzene contains few ions, which is not ideal for the use in electrophoresis. There are a number of buffers used for electrophoresis. The most common being, for nucleic acids Tris/Acetate/EDTA (TAE), Tris/Borate/EDTA (TBE). Many other buffers have been proposed, e.g. lithium borate (LB), (which is rarely used based on Pubmed citations), isoelectric histidine, pK matched Good's buffers, etc.; in most cases the purported rationale is lower current (less heat) matched ion mobilities, which leads to longer buffer life. Borate is problematic as borate can polymerize or interact with cis diols such as those found in RNA. TAE has the lowest buffering capacity, but provides the best resolution for larger DNA. This means a lower voltage and more time, but a better product. LB is relatively new and is ineffective in resolving fragments larger than 5 kbp; However, with its low conductivity, a much higher voltage could be used (up to 35 V/cm), which means a shorter analysis time for routine electrophoresis. As low as one base pair size difference could be resolved in 3% agarose gel with an extremely low conductivity medium (1 mM Lithium borate).
{\displaystyle \log D_{\text{oct/wat}}=\log _{10}\left({\frac {{\big [}{\text{solute}}{\big ]}_{\text{octanol}}^{\text{ionized}}+{\big [}{\text{solute}}{\big ]}_{\text{octanol}}^{\text{un-ionized}}}{{\big [}{\text{solute}}{\big ]}_{\text{water}}^{\text{ionized}}+{\big [}{\text{solute}}{\big ]}_{\text{water}}^{\text{un-ionized}}}}\right).}
== Nomenclature == All enzymes including radical SAM enzymes follow an easy guideline for systematic naming. Systematic naming of enzymes allows a uniform naming process that is recognized by all scientists to understand corresponding function. The first word of the enzyme name often shows the substrate of the enzyme. The position of the reaction on the substrate will also be in the beginning portion of the name. Lastly, the class of the enzyme will be described in the other half of the name which will end in suffix -ase. The class of an enzyme will describe what the enzyme is doing or changing on the substrate. For example, a ligase combines two molecules to form a new bond.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.